For example, in metastatic CRC, grouping the patients treated with first‐line bevacizumab + chemotherapy based on the changes of circulating miR‐126 disclosed a borderline significant separation of the groups in the progression‐free survival analysis favoring patients with decreasing miR‐126 levels, suggesting that it is worthy of consideration as a possible biomarker for the resistance to anti‐angiogenic containing treatments. 191 In radiochemotherapy‐treated neck and head
1
—
—